| Name | Title | Contact Details |
|---|
Exactech is a global medical device company that develops and markets orthopaedic implant devices, related surgical instruments and the Active Intelligence® platform of smart technologies to hospitals and physicians. Headquartered in Gainesville, Fla., Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Thanks for being a member of our community. Here a few guidelines to make your experience engaging, beneficial and excellent for everyone. We are a respectful community Exactech exists to help people improve their quality of life and regain their independence if they`ve been injured or developed arthritic disease. We strive to manage this community the same way we operate our business – with a commitment to our values of Integrity, Passion, Teamwork, Accountability and Innovation – and we all have to do our part to respect fellow community members. Therefore, any comment or post that includes profanity, hate speech, personal attacks, false or misleading information, off-topic information, off-label claims, political endorsements, spam or third-party solicitations, or violates any of LinkedIn`s Terms and Conditions will be removed. Duplicate posts may also be removed from our page. Posts may be removed at any time and at our discretion. Users who engage in prohibited conduct may be blocked from posting in our community without prior notice.
MJS BioLynx Inc. is a Brockville, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
TearLab Corporation develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation`s common shares trade on the NASDAQ Capital Market under the symbol `TEAR` and on the Toronto Stock Exchange under the symbol `TLB`. Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley’s Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide. The TearLab™ Osmolarity System provides the first quantitative and objective diagnostic technology that allows doctors to effectively manage their dry eye patients. TearLab will allow practitioners to diagnosis DED patients early in the disease process allowing for early intervention. TearLab received the CE Mark for its TearLab Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 14 countries including the US.
BioMedical Technology Solutions, Inc is a Englewood, CO-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
ULTRONICS is a Cuyahoga Falls, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.